Cormedix Stock Price, News & Analysis

CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its participation in the upcoming RBC Capital Markets Global Healthcare Conference. The event will be held in New York from May 20-21, 2025. The company will engage in a fireside chat format presentation scheduled for Wednesday, May 21, 2025, at 3:05 p.m. EDT. A webcast link will be available for interested parties to follow the presentation.

CorMedix Inc. (CRMD) reported strong Q1 2025 financial results with net revenue of $39.1 million and net income of $20.6 million ($0.32 per share), compared to a net loss in Q1 2024. The company achieved adjusted EBITDA of $23.6 million and positive cash flow from operations of $19.7 million. DefenCath sales drove performance, particularly in outpatient dialysis. The inpatient sales team is now fully operational, with institutional shipments doubling over three months. CorMedix commenced a Phase 3 study for reducing CLABSIs in TPN patients. The company expects to hit the high end of its H1 2025 sales guidance ($62-70 million) and reported cash and short-term investments of $77.5 million, sufficient for at least 12 months of operations.

CorMedix (Nasdaq: CRMD), a biopharmaceutical company developing therapeutic products for life-threatening diseases, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, before market opening.

The company will host a corporate update conference call at 8:30am Eastern Time on the same day. Interested parties can join through:

• Domestic call-in: 1-844-676-2922
• International call-in: 1-412-634-6840
• Conference ID: 10198548
• Webcast available via provided link

CorMedix (NASDAQ: CRMD) reports strong preliminary Q1 2025 results with unaudited net revenue of $39.0 million and expected adjusted EBITDA exceeding $22.5 million. The company's cash position stands at $77.5 million as of March 31, 2025.

Due to larger than anticipated orders in late March and improved visibility into customer inventory levels, CorMedix has raised its H1 2025 net sales guidance to $62-70 million. While Q2 2025 sales are expected to be lower than Q1 due to shipment timing, patient utilization is forecast to grow throughout 2025, with H2 shipments projected to exceed H1.

The company plans to begin patient enrollment for DefenCath's Phase 3 study in Total Parenteral Nutrition (TPN) patients in late April. If approved, DefenCath's peak annual sales potential in this indication is estimated at $150-200 million, with a total addressable market of $500-750 million.

CorMedix (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The event will be held virtually from April 7-10, 2025.

The company's management will engage in a Fireside Chat scheduled for Tuesday, April 8, 2025, at 2:15 p.m. EDT. This participation aligns with CorMedix's ongoing efforts to maintain investor relations and industry presence.

CorMedix (NASDAQ: CRMD) reported strong financial results for Q4 and full year 2024, marking its first profitable commercial quarter. The company achieved Q4 net revenue of $31.2 million and full-year revenue of $43.5 million, primarily driven by DefenCath sales since its outpatient launch in July 2024.

Q4 highlights include net income of $13.5 million and adjusted EBITDA of $15.3 million. The company ended 2024 with $51.7 million in cash and short-term investments. CorMedix provided preliminary guidance for H1 2025 with expected net revenue of $50-60 million, including over $33 million in Q1.

Key developments include partnering with Syneos Health for inpatient sales team building and WSI for VA facilities marketing. The company is preparing to commence a Phase 3 study of DefenCath in Total Parenteral Nutrition patients in Q2 2025, with a pending FDA Orphan Drug Status application.

CorMedix (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has scheduled its Q4 and Full Year 2024 financial results announcement. The company will release its financial performance report before market opens on March 25, 2025, followed by a corporate update conference call at 8:30am Eastern Time.

CorMedix (Nasdaq: CRMD), a biopharmaceutical company, has announced a collaboration with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities.

This partnership aims to enhance access to critical therapies for approximately 40,000 veterans living with end-stage renal disease (ESRD) and other beneficiaries of federal programs. WSI PBG will leverage its expertise in navigating VA and federal facilities, including access, procurement processes, and regulations, to meet the unique needs of these healthcare systems.

CorMedix and WSI PBG are committed to improving health outcomes by providing increased access to DefenCath for patients at VA and other federal facilities. Joe Todisco, CEO of CorMedix, expressed excitement about the collaboration, citing WSI PBG's deep understanding of the federal healthcare landscape as a key factor in enhancing access to DefenCath and ensuring equitable care for veterans and other federal healthcare beneficiaries.

CorMedix (NASDAQ: CRMD) reports strong preliminary Q4 2024 results with unaudited net revenue of approximately $31 million and full-year 2024 revenue of $43 million. Q4 adjusted EBITDA is expected to exceed $12 million, achieving the company's breakeven target by year-end 2024.

The company has secured over $25 million in open purchase orders for Q1 2025 delivery and is actively shipping DefenCath to three midsized dialysis operators. CorMedix plans to expand into the inpatient hospital segment in Q1 2025 through a partnership with Syneos Health for dedicated sales team deployment. The company projects FY 2025 operating expenses of $72-78 million, with increased R&D spending for clinical initiatives.

As of December 31, 2024, CorMedix maintains a strong financial position with approximately $52 million in cash and short-term investments.